Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glenvastatin SCHEMBL1040745 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL29557142 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL1040744 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL9872411 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL49508 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022892 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL1660022 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9527887 | 0.96 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022328 | 0.94 | HMGCR (0.89) | HMGCR | |
| SCHEMBL9023237 | 0.92 | HMGCR (0.85) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148550-B2 | selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups | RATIOPHARM GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20080249306-A1 | Method for the Production of Statins | RATIOPHARM GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20070093660-A1 | Method for the production of statins | RATIOPHARM GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093660-A1 | Method for the production of statins | HMGCR, CYP11A1, CYP51A1 | HMGCR 1/4885 |
| US-20080249306-A1 | Method for the Production of Statins | HMGCR, COASY, PCSK9 | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.